20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Abcellera Biologics Inc (ABCL) operates in the BIOTECHNOLOGY industry and is headquartered in Vancouver, Canada with about 562 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, ABCL reported $75M in revenue and ($146M) in net income.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Interactive charts & full statements → Open the ABCL valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $66M | $75M | $29M | $38M | $485M | $12M | $233M | $12M | $9M |
| Gross Profit | $50M | $46M | $29M | $38M | $419M | $12M | $206M | $12M | $9M |
| Gross Margin % | 75.0% | 61.6% | 100.0% | 100.0% | 86.3% | 100.0% | 88.4% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($225M) | ($217M) | ($315M) | ($237M) | $217M | ($4M) | $156M | ($4M) | ($1M) |
| Operating Margin % | -340.2% | -289.0% | -1091.7% | -623.8% | 44.6% | -35.5% | 66.9% | -35.4% | -8.5% |
| Net Income | ($165M) | ($146M) | ($163M) | ($146M) | $159M | ($2M) | $119M | ($2M) | $0M |
| Net Margin % | -248.8% | -194.9% | -564.8% | -385.0% | 32.7% | -19.0% | 51.0% | -19.0% | 3.5% |
| EBITDA | ($160M) | ($149M) | ($204M) | ($192M) | $260M | $0M | $170M | $0M | $1M |
| Earnings Per Share (EPS) | $-0.54 | $-0.49 | $-0.55 | $-0.51 | $0.50 | $-0.01 | $0.45 | $-0.01 | $0.00 |
| Shares Outstanding (M) | 306M | 299M | 294M | 289M | 315M | 318M | 263M | 238M | 151M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4M | $8M | $45M | $9M | $17M | $4M | $5M | $7M |
| Gross Profit | $4M | $0M | $37M | $9M | $17M | $4M | $5M | $7M |
| Gross Margin % | 100.0% | -4.1% | 82.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($63M) | ($58M) | ($29M) | ($76M) | ($50M) | ($63M) | ($73M) | ($94M) |
| Operating Margin % | -1550.0% | -691.8% | -63.7% | -851.8% | -290.2% | -1479.6% | -1440.7% | -1439.4% |
| Net Income | ($55M) | ($43M) | ($9M) | ($57M) | ($35M) | ($46M) | ($34M) | ($51M) |
| Net Margin % | -1368.6% | -519.1% | -19.9% | -637.8% | -203.3% | -1077.2% | -677.4% | -785.4% |
| EBITDA | ($42M) | ($41M) | ($12M) | ($66M) | ($39M) | ($52M) | ($55M) | ($52M) |
| Earnings Per Share (EPS) | $-0.18 | $-0.14 | $-0.03 | $-0.19 | $-0.12 | $-0.15 | $-0.12 | $-0.17 |
| Shares Outstanding (M) | 306M | 303M | 299M | 299M | 299M | 298M | 295M | 295M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($155M) | ($131M) | ($109M) | ($44M) | $277M | $245M | $23M | $3M | $4M |
| Capital Expenditures (CapEx) | $25M | $43M | $78M | $78M | $73M | $58M | $15M | $4M | $5M |
| Free Cash Flow (FCF) | ($179M) | ($174M) | ($187M) | ($121M) | $205M | $186M | $8M | ($1M) | ($2M) |
| FCF Margin % | -271.2% | -231.7% | -648.4% | -319.2% | 42.2% | 1603.0% | 3.4% | -11.2% | -19.7% |
| Dividends Paid | — | — | — | — | — | — | — | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($34M) | ($34M) | ($35M) | ($53M) | ($32M) | ($12M) | ($8M) | ($29M) |
| Capital Expenditures (CapEx) | $2M | $4M | $10M | $9M | $13M | $11M | $16M | $19M |
| Free Cash Flow (FCF) | ($36M) | ($37M) | ($45M) | ($62M) | ($46M) | ($22M) | ($24M) | ($48M) |
| FCF Margin % | -888.8% | -449.2% | -99.4% | -687.0% | -267.9% | -524.0% | -467.9% | -731.2% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B | $1.4B | $1.4B | $1.5B | $1.5B | $1.3B | $1.0B | $23M | $21M |
| Cash & Cash Equivalents | $120M | $129M | $156M | $133M | $387M | $476M | $594M | $8M | $10M |
| Total Liabilities | $412M | $390M | $304M | $336M | $308M | $293M | $175M | $13M | $10M |
| Total Debt (Short + Long-Term) | $6M | $6M | $5M | $6M | $6M | $4M | $3M | $4M | $3M |
| Total Shareholders' Equity | $896M | $967M | $1.1B | $1.2B | $1.2B | $1.0B | $831M | $10M | $12M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ABCL viewer.
About TickerBase · Data methodology & sources · Privacy · Terms